Alembic Pharmaceuticals announced its consolidated financial results for the first quarter ended June 30, 2026. The company reported a 26% year-on-year increase in revenue to ₹2150 crore and a 21% rise in EBITDA. Profit After Tax stood at ₹173 crore, up 12% YoY. Growth was driven by strong performance in both domestic and international markets, including a 49% surge in US formulations.
Alembic Pharmaceuticals Reports Resilient Q1 FY27 Performance
Alembic Pharmaceuticals Limited has declared its consolidated financial results for the first quarter of Fiscal Year 2027, ending June 30, 2026. The company showcased a robust performance, with revenue from operations increasing by 26% year-on-year to reach ₹2150 crore. Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA), before R&D expenses, grew by 21% year-on-year to ₹523 crore, maintaining a healthy margin of 24%.
Financial Highlights for Q1 FY27
The company’s financial performance for the quarter was marked by significant growth across key metrics:
- Revenue from operations: Increased by 26% YoY to ₹2150 crore.
- Profit After Tax (PAT): Stood at ₹173 crore, reflecting a 12% YoY growth.
- EBITDA (pre-R&D): Reached ₹523 crore, with a margin of 24%.
Management Commentary on Growth Drivers
Mr. Pranav Amin, Managing Director of Alembic Pharmaceuticals Limited, commented on the results, stating, “We have started FY27 on a strong note, delivering broad-based growth across our businesses. Performance during the quarter was driven by healthy volume growth, successful new product launches and continued execution across key markets. The US business delivered strong momentum, and the rest of the markets also recorded steady growth. We remain focused on strengthening our product portfolio, advancing our pipeline and driving sustainable long-term growth.”
Operational Highlights
The company detailed its performance across its business segments:
India Branded Business
- Achieved 7% YoY growth, contributing ₹642 crore in revenue for the quarter.
- Gynaecology, Gastrology, and Ophthalmology segments demonstrated robust growth.
- The Animal Healthcare segment also performed encouragingly.
- 3 new products were successfully introduced during the quarter.
International Business
- US Formulation sales grew by an impressive 49%, reaching ₹778 crore.
- 7 new product launches were executed in the US market.
- Ex-US Generics saw a growth of 17%, amounting to ₹383 crore.
- The company received 10 ANDA approvals during the quarter, bolstering its product pipeline for future launches.
API Business Performance
The Active Pharmaceutical Ingredient (API) business also demonstrated significant traction, with growth of 33%, generating revenue of ₹346 crore.
Summary of Revenue from Operations (Q1 FY26 vs. Q1 FY27)
| Particulars | Q1 FY26 (Rs in Cr.) | Q1 FY27 (Rs in Cr.) | % Change |
| Formulation | |||
| India | 599 | 642 | 7% |
| USA | 523 | 778 | 49% |
| Ex- US | 328 | 383 | 17% |
| API | 261 | 346 | 33% |
| Total | 1711 | 2150 | 26% |
Investor Call Scheduled
Alembic Pharmaceuticals Limited will host an investor call at 5:30 PM IST on August 4, 2026, to discuss the Company’s performance and answer questions from participants. Dial-in numbers for the conference call are +91 2262801411 or +91 2271158312.
Source: BSE
